Den Mark Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 4.47 M
as on 24-10-2024
- Company Age 3 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -2034.25%
(FY 2023)
- Ebitda -3015.03%
(FY 2023)
- Net Worth -14.94%
(FY 2023)
- Total Assets 210.78%
(FY 2023)
About Den Mark Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 4.47 M, as per Ministry of Corporate Affairs (MCA) records.
Samad Patanwala, Shahnazar, and Rida Patanwala serve as directors at the Company.
- CIN/LLPIN
U24304MH2021PTC372188
- Company No.
372188
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2021
- Date of AGM
22 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Den Mark Pharmaceuticals Private Limited offer?
Den Mark Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing, Cardiovascular Drugs & Medication, Blood Pressure Medicine, Digestive System Drugs & Medicines, Antacid Drugs, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Common Disease Medicines, Allopathic Cough Syrup.
Who are the key members and board of directors at Den Mark Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shahnazar  | Director | 04-Apr-2022 | Current |
| Samad Patanwala | Director | 25-Nov-2021 | Current |
| Rida Patanwala | Director | 25-Nov-2021 | Current |
Financial Performance of Den Mark Pharmaceuticals.
Den Mark Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 2034.25% decrease in profit. The company's net worth observed a substantial decline by a decrease of 14.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Den Mark Pharmaceuticals?
Unlock access to Den Mark Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Den Mark Pharmaceuticals?
Den Mark Pharmaceuticals has a workforce of 63 employees as of Aug 17, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Den Mark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Den Mark Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
